Forian Inc.
Forian Inc. builds proprietary information products, data management tools, and analytics solutions used to measure and improve operational, clinical, and financial performance. The company serves customers in healthcare and life sciences as well as financial services, with revenue generated from fees for information products and related services.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueData-driven information products sold under customer contracts for decision support and analysis.
Software and analytics offerings used to optimize operational, clinical, and financial outcomes.
Tools and services that organize, integrate, and manage customer data assets.
Implementation, client support, and related services tied to product delivery.
Products
Reported · share of revenue- Health Sciences Revenues75.9 %
- Financial Services Revenues24.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Forian sells primarily to organizations in healthcare and life sciences, where customers use its data and analytics to improve clinical, operational, and financial decisions. It also serves financial services clients, suggesting a mix of regulated enterprise buyers that value proprietary datasets and decision-support tools. Revenue is contract-based, so customer retention, renewal timing, and product relevance are important to growth.
Buy proprietary data, analytics, and performance tools to improve clinical and operational decisions.
Buy information products and analytics for research, risk, and decision support.
Buy data management and support services to integrate and operationalize information assets.
Strategy
Forian’s strategy appears centered on expanding its proprietary data and analytics platform across healthcare, life sciences, and financial services. The Kyber acquisition in October 2024 suggests a focus on adding capabilities and broadening the product set through M&A. Management also appears focused on improving cash generation and working capital discipline, which supports a data-services model that can be capital-light but execution-sensitive.
The acquisition can expand product capabilities and cross-sell opportunities.
Higher-value data products can strengthen customer stickiness and differentiation.
Operating cash flow supports flexibility in a business with acquisition and development needs.
Geography
Forian’s revenue is heavily concentrated in the United States, which accounted for 93% of sales in the three months ended March 31, 2025. Australia contributed 5% and Great Britain/others 2%, showing limited but real international exposure. The company’s geographic mix matters because its customer base, delivery model, and regulatory environment are centered in the U.S., while smaller overseas sales add some diversification.
Risks
Forian depends on contract-based revenue from proprietary data and analytics products, so customer retention, renewal timing, and product relevance are key risks. The business also faces integration risk from acquisitions like Kyber, plus typical software/data-service risks such as data licensing costs, hosting reliability, and competition for specialized analytics customers. Geographic concentration in the United States means the company remains exposed to U.S. healthcare and financial-services demand and regulation.
Revenue is derived from fees for proprietary information products and services under customer contracts.
Exposure: Contract timing and customer retention
The Kyber acquisition may create integration, retention, and execution challenges.
93% of Q1 2025 sales came from the U.S., limiting geographic diversification.
Exposure: U.S. healthcare and financial-services markets
Cost of revenues includes labor, information licensing, hosting, and infrastructure costs.
Exposure: Gross margin and service delivery economics
Accounting
Judgemental itemsManagement must judge whether obligations are distinct and recognized at a point in time or over time.
Impact: Can shift revenue between periods and affect comparability
Judgment is required to assess revenue under variable contracts.
Impact: Can create volatility in reported sales and margins
Expense depends on grant-date fair value and service-period assumptions.
Impact: Affects operating expense and non-cash earnings adjustments
Deferred tax asset realization depends on management estimates.
Impact: Can materially change tax expense and equity
Kyber was acquired under ASC 805, requiring purchase accounting and fair value estimates.
Impact: Can affect goodwill, intangibles, and future impairment risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Fortive Corp
FTV · Industrial Instruments For Measurement, Display, and Control
Fortive Corp is a U.S.-based industrial technology company that designs, manufactures, and services professional products, software, and connected workflow…
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
Forte Biosciences, Inc.
Pharmaceutical Preparations
Appian Corporation
APPN · Services-Prepackaged Software
Health Catalyst, Inc.
HCAT · Services-Computer Programming, Data Processing, Etc.
Health Catalyst builds cloud-based data and analytics software for healthcare organizations, combining a data platform, analytics applications, and implementation expertise.
Myriad Genetics, Inc
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
Last updated: 28/04/2026